Glenmark Pharma Receives ANDA Nod for Hydrocortisone Valerate Cream | CORPORATE ETHOS

Glenmark Pharma Receives ANDA Nod for Hydrocortisone Valerate Cream

By: | October 15, 2018
glenmark

Oct 15: Glenmark Pharmaceuticals Inc., USA, the US division of Mumbai-based drug maker Glenmark Pharmaceuticals Ltd, on Monday said that it has been granted final approval by the United States Food & Drug Administration (USFDA) for its Hydrocortisone Valerate Cream USP, 0.2%, a generic version of Westcort Cream, 0.2%, of Sun Pharmaceutical Industries Inc.

According to IQVIATM sales data for the 12-month period ending August 2018, the Westcort Cream, 0.2% market2 achieved annual sales of approximately $17.0 million.

Glenmark’s current portfolio consists of 139 products authorized for distribution in the US marketplace and 60 ANDA’s pending approval with the USFDA.